Related references
Note: Only part of the references are listed.Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives
Teodora Alexa et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Understanding the tumor microenvironment for effective immunotherapy
Habib Sadeghi Rad et al.
MEDICINAL RESEARCH REVIEWS (2021)
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
Long Yuan et al.
TRENDS IN IMMUNOLOGY (2021)
Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC
Yaru Tian et al.
CANCER MEDICINE (2021)
Mimicking Tumor Hypoxia in Non-Small Cell Lung Cancer Employing Three-Dimensional In Vitro Models
Iwona Ziolkowska-Suchanek
CELLS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Enrico Munari et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Jonathan Spicer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The Pandora's box of novel technologies that may revolutionize lung cancer
Habib Sadeghi Rad et al.
LUNG CANCER (2021)
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
Zhouhong Ge et al.
FRONTIERS IN IMMUNOLOGY (2021)
NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
Virginia Liberini et al.
CANCERS (2021)
Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment
Pankaj Ahluwalia et al.
CANCERS (2021)
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done
Lorenzo Belluomini et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment
Bailee H. Sliker et al.
VACCINES (2021)
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Reem Saleh et al.
SEMINARS IN CANCER BIOLOGY (2020)
New insight on the correlation of metabolic status on F-18-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer
Yang Wang et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins
Cedric Zeltz et al.
SEMINARS IN CANCER BIOLOGY (2020)
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)
J. Nicholas Bodor et al.
CANCER (2020)
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Kyohei Nakamura et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
VISTA: Coming of age as a multi-lineage immune checkpoint
M. A. ElTanbouly et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises
Kleita Michaelidou et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2020)
TLR3 Expression Induces Apoptosis in Human Non-Small-Cell Lung Cancer
Francesca Bianchi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Determinants of Resistance to Checkpoint Inhibitors
Linda Tran et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment
Shanshan Deng et al.
FRONTIERS IN ONCOLOGY (2020)
PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade
Marcel P. Trefny et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Induction of DNMT3B by PGE2 and IL6 at Distant Metastatic Sites Promotes Epigenetic Modification and Breast Cancer Colonization
Jae Young So et al.
CANCER RESEARCH (2020)
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Sara Saab et al.
FRONTIERS IN IMMUNOLOGY (2020)
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
Delvys Rodriguez-Abreu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Chongxian Pan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC
Lingzhi Hong et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Alireza Labani-Motlagh et al.
FRONTIERS IN IMMUNOLOGY (2020)
Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk
Poonam Sarode et al.
FRONTIERS IN ONCOLOGY (2020)
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer
Margaux Hubert et al.
SCIENCE IMMUNOLOGY (2020)
Clinical Challenges of Immune Checkpoint Inhibitors
Maria de Miguel et al.
CANCER CELL (2020)
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
Shin Foong Ngiow et al.
FRONTIERS IN IMMUNOLOGY (2020)
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion
Paola De Cicco et al.
FRONTIERS IN IMMUNOLOGY (2020)
Tim-3 finds its place in the cancer immunotherapy landscape
Nandini Acharya et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
Xing Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Reem Saleh et al.
CANCER LETTERS (2020)
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)-novel approaches and future outlook
Lena Horvath et al.
MOLECULAR CANCER (2020)
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
Shogo Kumagai et al.
NATURE IMMUNOLOGY (2020)
LAG-3: from molecular functions to clinical applications
Takumi Maruhashi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
TIGIT in cancer immunotherapy
Joe-Marc Chauvin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers
Irina Larionova et al.
FRONTIERS IN ONCOLOGY (2020)
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Rilan Bai et al.
BIOMARKER RESEARCH (2020)
Cancer-associated fibroblasts an their influence on tumor immunity and immunotherapy
Richard Lee Barrett et al.
ELIFE (2020)
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
Laura Boyero et al.
CANCERS (2020)
Neutrophil diversity and plasticity in tumour progression and therapy
Sebastien Jaillon et al.
NATURE REVIEWS CANCER (2020)
The cancer-natural killer cell immunity cycle
Nicholas D. Huntington et al.
NATURE REVIEWS CANCER (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis
Kumar S. Bishnupuri et al.
CANCER RESEARCH (2019)
The innate immune architecture of lung tumors and its implication in disease progression
Simon Milette et al.
JOURNAL OF PATHOLOGY (2019)
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal et al.
NATURE (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Mikhail Binnewies et al.
CELL (2019)
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
Yanhui Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC
Sehhoon Park et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
M2 macrophages promote NSCLC metastasis by upregulating CRYAB
Zhe Guo et al.
CELL DEATH & DISEASE (2019)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
Denarda Dangaj et al.
CANCER CELL (2019)
Tumour-associated neutrophils in patients with cancer
Merav E. Shaul et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Amy L. Shergold et al.
PHARMACOLOGICAL RESEARCH (2019)
Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma
Malgorzata Czystowska-Kuzmicz et al.
NATURE COMMUNICATIONS (2019)
Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
Barbara Seliger
FRONTIERS IN IMMUNOLOGY (2019)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L. Topalian et al.
JAMA ONCOLOGY (2019)
Tumor mutation burden: from comprehensive mutational screening to the clinic
Francesca Galuppini et al.
CANCER CELL INTERNATIONAL (2019)
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
Seung Eun Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
Arsen Osipov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer
Hye Ryun Kim et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Identification of differentially expressed genes in non-small cell lung cancer
Ke Wang et al.
AGING-US (2019)
The circulating pool of functionally competent NK and CD8+cells predicts the outcome of anti-PD1 treatment in advanced NSCLC
Giulia Mazzaschi et al.
LUNG CANCER (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity
Mohamed A. ElTanbouly et al.
SEMINARS IN IMMUNOLOGY (2019)
The lung microenvironment: an important regulator of tumour growth and metastasis
Nasser K. Altorki et al.
NATURE REVIEWS CANCER (2019)
Hypoxia-Modified Cancer Cell Metabolism
Wafaa Al Tameemi et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Fates of CD8+ T cells in Tumor Microenvironment
Nomathamsanqa Resegofetse Maimela et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Reverse of non-small cell lung cancer drug resistance induced by cancer-associated fibroblasts via a paracrine pathway
Quanhui Zhang et al.
CANCER SCIENCE (2018)
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Immune cell landscape in therapy-naive squamous cell and adenocarcinomas of the lung
Luka Brcic et al.
VIRCHOWS ARCHIV (2018)
Expression of PD-1 on CD4+ Tumor-Infiltrating Lymphocytes in Tumor Microenvironment Associated with Pathological Characteristics of Breast Cancer
Yan-Jie Zhao et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Jonathan A. Trujillo et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Alex M. Abel et al.
FRONTIERS IN IMMUNOLOGY (2018)
Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors
David Argyle et al.
FRONTIERS IN IMMUNOLOGY (2018)
Natural killer cells and other innate lymphoid cells in cancer
Laura Chiossone et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer
Franz Villarroel-Espindola et al.
CLINICAL CANCER RESEARCH (2018)
CD226 opposes TIGIT to disrupt Tregs in melanoma
Julien Fourcade et al.
JCI INSIGHT (2018)
Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value
Giulia Mazzaschi et al.
CLINICAL CANCER RESEARCH (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens et al.
EUROPEAN JOURNAL OF CANCER (2017)
Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer
Nicholas A. Taylor et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Tumor-associated macrophages: from basic research to clinical application
Li Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
Yayi He et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma
Zhi-Zhang Yang et al.
ONCOTARGET (2017)
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer
Yunjian Pan et al.
JOURNAL OF THORACIC DISEASE (2017)
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Patricia Gaule et al.
JAMA ONCOLOGY (2017)
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Aleix Prat et al.
CANCER RESEARCH (2017)
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation
Jonathan E. Schoenhals et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer
Jing Liu et al.
CANCER RESEARCH (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Follicular regulatory T cells repress cytokine production by follicular helper T cells and optimize IgG responses in mice
Hao Wu et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
A High-Dimensional Atlas of Human T Cell Diversity Reveals Tissue-Specific Trafficking and Cytokine Signatures
Michael Thomas Wong et al.
IMMUNITY (2016)
Identification of CD112R as a novel checkpoint for human T cells
Yuwen Zhu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase
Takashi Inozume et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Neutrophil-derived chemokines on the road to immunity
Cristina Tecchio et al.
SEMINARS IN IMMUNOLOGY (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors
Ameet K. Mishra et al.
ONCOTARGET (2016)
Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis
Sha Zhao et al.
ONCOTARGET (2016)
Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway
Leilei Tao et al.
SCIENTIFIC REPORTS (2016)
Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy
Shuhong Qi et al.
ELIFE (2016)
Increased Levels of Circulating and Tumor-Infiltrating Granulocytic Myeloid Cells in Colorectal Cancer Patients
Salman M. Toor et al.
FRONTIERS IN IMMUNOLOGY (2016)
Macrophage and Cancer Cell Cross-talk via CCR2 and CX3CR1 Is a Fundamental Mechanism Driving Lung Cancer
Anja Schmall et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
Liyun Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients
Joe-Marc Chauvin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment
Thomas F. Gajewski
SEMINARS IN ONCOLOGY (2015)
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
Bin Shang et al.
SCIENTIFIC REPORTS (2015)
Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response
S. R. McKeown
BRITISH JOURNAL OF RADIOLOGY (2014)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Christiane Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets
Steven L. Wood et al.
CANCER TREATMENT REVIEWS (2014)
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1-or Melan-A-Specific T Cells
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2014)
Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
Nicole Joller et al.
IMMUNITY (2014)
Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
Peter J. Murray et al.
IMMUNITY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
The effect of immune microenvironment on the progression and prognosis of colorectal cancer
Jinxiang Chen et al.
MEDICAL ONCOLOGY (2014)
Galectin Expression Profiling Identifies Galectin-1 and Galectin-9Δ5 as Prognostic Factors in Stage I/II Non-Small Cell Lung Cancer
Iris A. Schulkens et al.
PLOS ONE (2014)
Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Ana C. Anderson
CANCER IMMUNOLOGY RESEARCH (2014)
Galectin-9 in tumor biology: A jack of multiple trades
Roy Heusschen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2013)
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Justin F. Gainor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Tim-3 Expression Defines Regulatory T Cells in Human Tumors
Jing Yan et al.
PLOS ONE (2013)
Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival
Patricia Gonzalez-Arriaga et al.
BMC CANCER (2012)
Lysyl Oxidase May Play a Critical Role in Hypoxia-Induced NSCLC Cells Invasion and Migration
Ling Wei et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells
Hiroyuki Tao et al.
LUNG CANCER (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
Xin Gao et al.
PLOS ONE (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Nicole Joller et al.
JOURNAL OF IMMUNOLOGY (2011)
Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
Dallas B. Flies et al.
JOURNAL OF IMMUNOLOGY (2011)
Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes
Maxime Chapon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma
Reiko Nakai et al.
CANCER SCIENCE (2010)
LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
Chiara Camisaschi et al.
JOURNAL OF IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
Masafumi Nakayama et al.
BLOOD (2009)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
Kent S. Boles et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Natural Tregs and autoimmunity
Antonio La Cava
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Neutrophils: key mediators of tumour angiogenesis
Simon Tazzyman et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2009)
Genome-wide Association of Hypoxia-inducible Factor (HIF)-1α and HIF-2α DNA Binding with Expression Profiling of Hypoxia-inducible Transcripts
David R. Mole et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
CANCER Inflaming metastasis
Alberto Mantovani
NATURE (2009)
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
Sunhwa Kim et al.
NATURE (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer
Wiebke Sauter et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Imaging of the hypoxia-inducible factor pathway: insights into oxygen sensing
U. Berchner-Pfannschmidt et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Role of innate immune cells and their products in lung immunopathology
Tomoko Suzuki et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1
S. Seth et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Identification of Tim4 as a phosphatidylserine receptor
Masanori Miyanishi et al.
NATURE (2007)
Differential antigen processing by dendritic cell subsets in vivo
Diana Dudziak et al.
SCIENCE (2007)
An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers
QT Le et al.
CLINICAL CANCER RESEARCH (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
CD155/PVR plays a key role in cell motility during tumor cell invasion and migration
KE Sloan et al.
BMC CANCER (2004)
Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response
P Vaupel et al.
ONCOLOGIST (2004)
CD226 mediates platelet and megakaryocytic cell adhesion to vascular endothelial cells
H Kojima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule
C Bottino et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance
A Sanchez-Fueyo et al.
NATURE IMMUNOLOGY (2003)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Involvement of granzyme B and perforin in suppressing nodal metastasis of cancer cells in breast and lung cancers
K Kontani et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
